Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO.

Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H.

Cancer Res. 2010 Jan 15;70(2):552-9. doi: 10.1158/0008-5472.CAN-09-2653. Epub 2010 Jan 12.

2.

MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.

Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H.

J Med Genet. 2006 Jun;43(6):501-6. Epub 2005 Sep 16.

3.

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, Petersen GM.

Eur J Hum Genet. 2011 Apr;19(4):472-8. doi: 10.1038/ejhg.2010.198. Epub 2010 Dec 8.

4.

Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.

Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group.

J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15.

PMID:
16234564
5.
6.

CDKN2A germline mutations in familial pancreatic cancer.

Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H.

Ann Surg. 2002 Dec;236(6):730-7.

7.

Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations.

Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, MacK P, Baglietto L, Cuzick J, Bishop DT.

J Invest Dermatol. 2000 Jan;114(1):28-33.

8.

CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.

Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J.

Cancer Res. 2000 Dec 15;60(24):6864-7.

9.

Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.

Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarrà G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.

Genes Chromosomes Cancer. 2001 Nov;32(3):195-202.

PMID:
11579459
10.

Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.

Abdel-Rahman MH, Pilarski R, Massengill JB, Christopher BN, Noss R, Davidorf FH.

Melanoma Res. 2011 Jun;21(3):175-9. doi: 10.1097/CMR.0b013e328343eca2.

PMID:
21412176
11.

CDKN2A as a uveal and cutaneous melanoma susceptibility gene.

Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B.

Genes Chromosomes Cancer. 2003 Nov;38(3):265-8.

PMID:
14506702
12.

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE.

Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63. Erratum in: Genes Chromosomes Cancer. 2007 Jul;46(7):716.

PMID:
17001621
13.

CDKN2A mutations in multiple primary melanomas.

Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ.

N Engl J Med. 1998 Mar 26;338(13):879-87.

14.

Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.

van der Rhee JI, Boonk SE, Putter H, Cannegieter SC, Flinterman LE, Hes FJ, de Snoo FA, Mooi WJ, Gruis NA, Vasen HF, Kukutsch NA, Bergman W.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1771-7. doi: 10.1158/1055-9965.EPI-13-0130. Epub 2013 Jul 29.

15.

Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.

de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA.

Clin Cancer Res. 2008 Nov 1;14(21):7151-7. doi: 10.1158/1078-0432.CCR-08-0403.

16.

Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.

Peric B, Cerkovnik P, Novakovic S, Zgajnar J, Besic N, Hocevar M.

BMC Med Genet. 2008 Sep 19;9:86. doi: 10.1186/1471-2350-9-86.

17.

A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.

Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Bressac-de Paillerets B.

Eur J Hum Genet. 2003 Apr;11(4):288-96.

18.

Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.

Cabanillas R, Astudillo A, Valle M, de la Rosa J, Álvarez R, Durán NS, Cadiñanos J.

Head Neck. 2013 Mar;35(3):E80-4. doi: 10.1002/hed.21911. Epub 2011 Nov 15.

PMID:
22083977
19.

New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.

Kannengiesser C, Dalle S, Leccia MT, Avril MF, Bonadona V, Chompret A, Lasset C, Leroux D, Thomas L, Lesueur F, Lenoir G, Sarasin A, Bressac-de Paillerets B.

Genes Chromosomes Cancer. 2007 Aug;46(8):751-60.

PMID:
17492760
20.

Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.

Platz A, Hansson J, Månsson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganäs M, Ringborg U.

J Natl Cancer Inst. 1997 May 21;89(10):697-702.

PMID:
9168184

Supplemental Content

Support Center